The primary goals of antiplatelet therapy in peripheral artery disease are the prevention of cardiovascular ischaemic events and maintenance of revascularization patency. Vorapaxar is a novel agent that has a demonstrated clinical benefit in a broad population of patients, and also decreases the progression of limb ischaemia.
